51 results about "Inflammation Process" patented technology

The invention relates to application of bifidobacterium animalis subsp. Lactis in preparation of a preparation for preventing and / or treating allergic rhinitis. The bifidobacterium animalis subsp. Lactis comprises Bifidobacterium animalis subsp. Lactis BGI-N3, the Bifidobacterium animalis subsp. Lactis BGI-N3 is preserved in the China Center for Type Culture Collection on October 17, 2022, and the preservation number of the Bifidobacterium animalis subsp. Lactis BGI-N3 is CCTCC (China Center for Type Culture Collection) NO: M20221585. Based on an allergic rhinitis animal model, the action mechanism of the animal bifidobacterium subsp. Lactis in the inflammation process is deeply analyzed, it is found that the animal bifidobacterium subsp. Lactis can effectively prevent and / or treat allergic rhinitis, and a new strategy is provided for developing a scheme for treating allergic rhinitis.

A method of treating Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: providing a subject with an effective amount of a modified tetracycline or derivative thereof to ameliorate or eliminate the AUD, SUD, tobacco use, pain, or proinflammatory disorder, and wherein the modified tetracycline or derivative thereof has reduced binding to a microbial ribosome and has the formula:wherein R1 is acetyl, R2 is OH or acetyl, R3 is acetyl, R4 is H or acetyl, and R5 is acetyl.

An Interferon Gamma Inducible Protein 16 (IFI16) mutant gene and its use as a marker for predicting, diagnosing, or prognosticating risk or severity of chronic liver disease is described. As a result of performing genomic analysis on NAFLD and NASH patient groups, it was confirmed that the frequency of IFI16 single-nucleotide variants (SNVs) including rs2276404, rs73021847, rs7532207, and rs6940 was increased, and the expression of the IFI16 mutant gene was increased depending on the disease stage of liver disease. The IFI16 SNV was highly expressed in infiltrating macrophages, playing a role in macrophage-induced inflammatory processes, and the IFI16 variant bound more strongly to dsDNA than wild-type IFI16, exacerbating the impaired mitochondrial DNA-sensing response signaling of the IFI16-PYCARD-CASP1 pathway. Thus, the IFI16 mutant gene may be used for predicting, diagnosing, or prognosticating risk or severity of chronic liver disease.

The present invention relates to a method for preparing a coating composition comprising an anti-infective agent for the controlled release of said anti-infective agent, and to a coating composition or coated substrate obtainable by said method. Such coating compositions are particularly useful in the dental field for the treatment or prevention of inflammatory processes, such as mucositis or peri-implantitis, preferably peri-implantitis.

To provide a novel tetracycline derivative having reduced antimicrobial activity for use in treating disorders of the central nervous system.SOLUTION: Provided are novel molecules comprising a modified tetracycline molecule including Deamino Diacetyl Minocycline, Methyl Ether Minocycline, Ethyl Ether Minocycline, Propyl Ether Minocycline, Butyl Ether Minocycline, Butyl Ether Monoacetyl Minocycline, Butyl Ether Diacetyl Minocycline, Butyl Ether Triacetyl Minocycline, or Butyl Ether Tetra Acetyl Minocycline, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, and tautomers thereof, and methods for using the same to treat Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders.SELECTED DRAWING: None

The present invention relates to a composition, as well as a tablet, capsule or juice for oral administration, and its use as an anti-aging agent. The present invention also relates to the use of a composition, tablet, capsule or juice, for providing a balanced protein supply, and / or for improving the utilization of amino acids in a cell and / or in an organism. In addition, the present invention also relates to the use of a composition, a tablet, a capsule or a juice, for increasing the build-up of muscle mass, for stimulating metabolic performance, for positively influencing inflammatory processes, and / or for positively influencing the aging process of a cell and / or an organism. The present invention also relates to a composition, a tablet, a capsule or a juice, for use as a medicament. Furthermore, the present invention also relates to a composition, tablet, capsule or juice, for use in a method for the prevention or treatment of age-related disorders and / or diseases.

The present invention combines the drugs desloratadine and betamethasone in a single dosage unit, which represents a set of important technological challenges due to the physicochemical properties and the difference in doses to guarantee obtaining a stable product for the treatment of allergic and inflammatory processes in a subject.

Compositions and methods for controlling chronic inflammation in a patient are provided herein. The compositions and methods use D6-arachidonic acid or its esters (D6-AA) as an anti-inflammatory agent that results in a significant reduction in the inflammatory process. In addition, the deuterated arachidonic acid or its ester compositions contain, on average, at least about 80% of the hydrogen atoms at each bis-allylic position replaced by deuterium atoms, and, on average, no more than about 30% of the hydrogen atoms at the mono-allylic positions replaced by deuterium atoms.

The present invention relates to a process for synthesising non-steroidal anti-inflammatory compounds derived from spilanthol. The present invention provides a highly desirable optimised process for the development of new anti-inflammatory agents, being an alternative to corticosteroids which present serious side effects with long-term use. The compounds disclosed in the present invention have applications in the pharmaceutical industry, since they have the potential to be used in the treatment of diseases that involve the development of inflammatory processes, such as migraines, rheumatism, osteoarthritis, infections or orthopaedic injuries.

A personal system to collect and remove electromagnetic radiation (EMR) and excess magnetic and voltage fields from a human body includes portable and non-portable embodiments that, when applied to skin, can causes EMR fields to be drawn out of the body toward a magnet before which the wave is split into separate electrical and the magnetic fields at the surface of the containers. Extraneous magnetic fields coming from the body are absorbed into the magnetic field of the internal magnet while simultaneously donating electrons and creating electrical current within the body to reduce oxidative stress inflammation. A portable handheld system includes a fanny / back pack, a revised standard insulated conductive grounding cord and a specialized cap for mobile use of standard grounding equipment. The system includes more high-powered non-portable similarly functioning EMR-removing vacuum-like booster instruments and protective wearable outer gear.

The invention provides a method for extracting kapur through compound bacterium fermentation, which comprises the following steps: drying leaves of kapur burmannii chvar.Borneol by microwaves, mixing and crushing to obtain leaf powder, adding a compound enzyme of xylanase, hemicellulase, lipase and pectinase for enzymolysis, taking a citric acid-sodium citrate buffer solution as a solvent, carrying out enzymolysis, heating for inactivation, filtering, washing, and drying to obtain a finished product. The borneol type cinnamomum burmannii leaves are obtained by fermenting the borneol type cinnamomum burmannii leaves with a complex microbial inoculant, extracting a fermentation product with an ionic liquid-ethanol mixed solution, extracting with petroleum ether, condensing and refluxing with absolute ethyl alcohol and performing vacuum drying to remove an organic solvent, the yield of the borneol type cinnamomum burmannii leaves is high, release of IFN-beta and IL-6 inflammatory mediators can be remarkably reduced, inflammatory response is relieved, and the borneol type cinnamomum burmannii leaves are prepared. The inflammation process is inhibited, the effect of treating or preventing chronic pharyngitis is achieved, and the effects of improving sleep and relieving emotion are achieved.

The present invention relates to the field of medicine and provides pharmaceutical compositions comprising one or more isolated amino acid sequences comprising or consisting solely of SEQ ID NO: 3 and / or SEQ ID NO: 1 and / or SEQ ID NO: 2, kits and conjugates comprising one or more of the aforementioned amino acid sequences. Furthermore, the present invention relates to the use of the pharmaceutical compositions, kits and conjugates of the present invention as medicaments, in particular in the treatment of infectious diseases or inflammatory conditions associated with infectious diseases or inflammatory diseases associated with the presence of products derived from infectious pathogens. The present invention also provides a device for selectively binding and separating at least one component from an aqueous solution, the device comprising one or more of the aforementioned amino acid sequences. [Selection diagram] None

This application discloses novel substituted pyridazine compounds and analogues, their preparation, pharmaceutical compositions comprising them, and their therapeutic uses as medicaments for treating diseases or disorders associated with modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3, or inhibition of the activation of NLRP3 or related components of the inflammatory process.

The invention relates to the fields of therapy and drug delivery. It is based on an unexpected finding that a combination of an oligonucleotide-based medicament with a saponin component comprising a penta-cyclic triterpene saponin of a 12,13-dehydrooleanane aglycone core, not only does not appear to be associated with oligonucleotide medicament-induced nephrotoxic effects after systemic administration in vivo, but also that it allows the oligonucleotide-based medicament to enter and act on its nucleic acid target inside of the kidney cells instead of remaining unproductively trapped in renal subcellular compartments or being eliminated into the urine via the renal glomerular filtration system. In line with this finding, herein disclosed are therapeutic combinations, compositions, and formulations, as well as methods of treatment involving their administration, which comprise an oligonucleotide-based medicament that acts on an intracellular nucleic acid target in the kidney cells and / or in the cells of the spleen, being the other blood filtering organ in addition to the kidney, and a saponin component that enables the effective release of said medicament inside of these cells, thus allowing its use at a much lower and safer dose. The provision of the presented herein therapeutic combinations enables effective modulation of gene expression in the kidney and / or spleen cells and, therefore, it opens not only new treatment options for kidney diseases, in particular those involving inflammation and / or splenomegaly, but also for diseases of other organs which affect or are affected by the pathological processes happening in the kidneys and / or in the spleen, in particular being inflammatory processes.

A preparation consisting of active components made up of fish oil (as a source of omega-3 fatty acids, i.e. EPA and DHA), blackcurrant seed oil (as a source of omega-6 fatty acids, i.e. GLA) and vitamin D3, which has synergy action on skin disorders in children, such as skin inflammation, itching, eczema, atopic dermatitis because it allows the use of lower individual doses of each active ingredient that target different points in the skin inflammation process.

The present invention describes new cosmetic, cosmeceutical and / or pharmaceutical compositions, as well as their uses and useful methods for alleviating conditions arising from inflammatory processes, sensitive skin, rosacea, atopic dermatitis, eczema, and / or for alleviating the sensation of discomfort and pain, modulating the CB2 receptor, and / or for improving problems relating to cutaneous hyperchromia and disorders relating to increased sebogenesis.

The present invention relates to a composition comprising a combination of at least two cosmetic active agents, said combination of active agents preventing or reducing the loss of proteostasis, preventing or reducing micro-inflammatory processes, preventing cellular senescence, and preventing or reducing mitochondrial dysfunction and / or stimulating mitochondrial energy metabolism in skin cells The invention also relates to the cosmetic use of such a composition for increasing the longevity of skin cells and skin tissues, for preventing or reducing the loss of proteostasis, preventing or reducing micro-inflammatory processes, preventing cellular senescence and preventing or reducing mitochondrial dysfunction and / or stimulating mitochondrial energy metabolism, in skin cells. Finally, the invention relates to a nontherapeutic cosmetic process for caring for keratin materials comprising the topical application of such a composition.

The invention discloses a reagent composition for constructing an acute inflammation model and a construction method. In the invention, local slow release of TNF-alpha is realized through the temperature-sensitive hydrogel, the limitation of traditional systemic administration is broken through, the gradient diffusion characteristic of inflammatory factors in a focus area is restored, and model distortion caused by excessive activation of systemic immune response is avoided. The stepped delivery of the lipopolysaccharide, the prostaglandin E2 analogue and the IL-1beta histamine aerosol effectively covers key pathological links such as vascular permeability change, neutrophil infiltration, oxidative stress and the like through multi-channel synergistic amplification of an inflammation cascade effect. Dynamic balance maintenance of the active oxygen scavenger significantly improves the stability of the model, ensures that the inflammation process is controllable and reversible, provides a reliable window period for drug testing, and real-time fluorescence monitoring and end-point multi-index joint inspection form a closed-loop verification system, so that dynamic migration characteristics of inflammation can be captured, the end damage degree can be quantified, and the accuracy of drug detection is improved. And a complete data link from a process to a result is provided for mechanism research.

The inventions relate to medical equipment and characterize a ventilated ozonizing drainage and lavage kit, and a drainage catheter, an aspirator and an ozonator contained in said kit, as well as a method for the prophylaxis and treatment of destructive inflammatory processes. The inventions are intended to provide reliable thorough long-term atraumatic active and passive drainage, as well as ease of use.

The application discloses a gynecological micro-ecological detection system based on AI multi-modal fusion, and belongs to the technical field of gynecological micro-ecological detection. The system comprises a data acquisition module, a standardization module and a micro-ecological output unit. The data acquisition module acquires immunofluorescence signals, gram staining morphological characteristics and dry chemical indexes. The data acquisition module is connected to the standardization module. The standardization module comprises a pre-processing unit for pre-processing collected data. The standardization module is connected with a data classification unit for data classification. The data classification unit is connected to a heterologous data normalization processing unit. The gynecological micro-ecological detection system based on AI multi-modal fusion can realize accurate evaluation of gynecological micro-ecology, construct a dynamic model of microbial community parameters, realize inflammation process quantification, generate a visual micro-ecological atlas through three-dimensional space mapping, and output inflammation types and overall micro-ecological evaluation.

The present invention relates to a polyhydroxylated chiral carbon-based nanometric cluster derived from plant-based materials called Micronized Vegetal Carbon NCN (NITE Carbon Nano Cluster - NITE NCN Pet) for use in a method of treatment, preventive and / or adjuvant to the curative process, of diseases and / or disorders characterized by inflammatory processes on an oxidative basis, such as those observed in musculoskeletal and / or osteoarticular diseases and / or disorders, in a mammal in need thereof. The present invention also relates to a feed ingredient comprising said polyhydroxylated chiral carbon-based nanometric cluster derived from plant-based materials called Micronized I Carbon NCN (NITE Carbon Nano Cluster - NITE NCN Pet) for use in a method of treatment, preventive and / or adjuvant to the curative process, of diseases and / or disorders of the musculoskeletal and / or osteoarticular system, in a mammal in need thereof.

The present invention relates to the use of 3-arylphthalides and derivatives thereof as anti-inflammatory agents. The invention relates to the use of 3-arylphthalides, in particular 3-(4,5-dihydroxy-2-(2-5 ethylthio)ethylphenyl)phthalide and 3-(2,4-dihydroxyphenyl)phthalide, as anti-inflammatory and chemopreventive agents in inflammatory processes in general, in diseases caused by underlying inflammation processes and in inflammatory processes related to the development of diabetes mellitus and its complications.

This application discloses novel macrocycle compounds of formula (I) and analogues, their preparation, pharmaceutical compositions comprising them, and their therapeutic uses as medicaments for treating diseases or disorders associated with modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3, or inhibition of the activation of NLRP3 or related components of the inflammatory process.

The invention belongs to the technical field of fluorescent probes, and particularly relates to a near-infrared fluorescent probe for carbon monoxide monitoring in an inflammation process as well as a preparation method and application of the near-infrared fluorescent probe. Based on a donor-receptor system of dicyanoisofuranone and 2-mercaptoaniline, a compound containing benzothiazole, dicyanomethylene and allyl carbonate diester is prepared as a near-infrared probe, and a sensing mechanism is based on palladium-mediated allyl carbonate connecting bond breakage and release of high fluorophore, so that a remarkable fluorescence opening effect is generated. Visual monitoring of fluctuation of the carbon monoxide level in the zebra fish inside and outside the organism under inflammation stimulation is achieved, and a reliable tool is provided for studying in-vivo distribution and physiological functions of carbon monoxide.

The present invention relates to the delivery of galectins useful in the control of inflammation in diseases associated with inflammatory processes, such as intestinal inflammatory diseases. More particularly, the present invention relates to the delivery of Galectin-1 (Gal1) and Gal1-variants for controlling inflammation in such diseases. More specifically, the present invention relates to the treatment of Intestinal Inflammatory Diseases, in particular ulcerative colitis (UC) and Crohn's disease (CD). Even more specifically, the present invention relates to optimized lactic-acid bacterial strains, capable of producing and secreting considerable levels of human Gal1 and Gal1 variants for delivering galectin-1 into the inflamed tissue. Also, the present invention relates to expression cassettes comprising those Gal1 and variants thereof and the vectors wherein said expression cassettes are contained.

Cosmetic composition for skin cell longevity The present invention relates to a composition comprising a combination of at least two cosmetic active agents, said combination of active agents preventing epigenetic modifications, preventing or reducing the loss of proteostasis, preventing or reducing micro- inflammatory processes, and preventing or reducing mitochondrial dysfunction and / or stimulating mitochondrial energy metabolism in skin cells The invention also relates to the cosmetic use of such a composition for increasing the longevity of skin cells and skin tissues, preventing epigenetic modifications, preventing or reducing the loss of proteostasis, preventing or reducing micro-inflammatory processes, and preventing or reducing mitochondrial dysfunction and / or stimulating mitochondrial energy metabolism, in skin cells. Finally, the invention relates to a nontherapeutic cosmetic process for caring for keratin materials comprising the topical application of such a composition.